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Abstract
Background—Myocardial infarction (MI) is a leading cause of heart failure and death 
worldwide. Preservation of contractile function and protection against adverse changes in
ventricular architecture (cardiac remodeling) are key factors to limiting progression of this 
condition to heart failure. Consequently, new therapeutic targets are urgently required to achieve 
this aim. Expression of the Runx1 transcription factor is increased in adult cardiomyocytes 
following MI; however, the functional role of Runx1 in the heart is unknown.  
Methods—To address this question, we have generated a novel tamoxifen-inducible 
cardiomyocyte-specific Runx1-deficient mouse. Mice were subjected to MI by means of 
coronary artery ligation. Cardiac remodeling and contractile function were assessed extensively 
at the whole heart, cardiomyocyte and molecular levels. 
Results—Runx1 deficient mice were protected against adverse cardiac remodeling post-MI, 
maintaining ventricular wall thickness and contractile function. Furthermore, these mice lacked 
eccentric hypertrophy and their cardiomyocytes exhibited markedly improved calcium handling. 
At the mechanistic level, these effects were achieved through increased phosphorylation of 
phospholamban by PKA and relief of sarcoplasmic reticulum calcium pump (SERCA) inhibition. 
Enhanced SERCA activity in Runx1 deficient mice increased sarcoplasmic reticulum calcium
content and sarcoplasmic reticulum-mediated calcium release, preserving cardiomyocyte 
contraction post-MI. 
Conclusions—Our data identified Runx1 as a novel therapeutic target with translational 
potential to counteract the effects of adverse cardiac remodeling, thereby improving survival and 
quality of life among patients with MI.
Key Words: cardiac myocyte; infarction; remodeling; calcium regulation; excitation-contraction 
coupling; Runx1 
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Clinical Perspective 
What is new? 
? Our study provides new evidence that Runx1, a gene intensively studied in the cancer and 
blood research fields, has a critical role in cardiomyocytes following myocardial 
infarction (MI).
? We provide conclusive evidence that increased Runx1 expression under pathological 
conditions leads to decreased cardiac contractile function. 
? Experiments performed utilizing a newly generated cardiomyocyte-specific Runx1 
deficient mouse reveal that reducing Runx1 function preserves myocardial contractility 
and prevents adverse cardiac remodeling post-MI.
What are the clinical implications?
? Our mechanistic data robustly demonstrate that Runx1 modulates cardiac sarcoplasmic 
reticulum (SR) calcium uptake and contractile function.
? Reducing Runx1 function drives increased contractility post-MI, thereby preserving LV 
systolic function and preventing adverse cardiac remodeling.  
? Our study therefore importantly identifies Runx1 as a new target holding major promise 
for limiting the progression to heart failure among patients with MI by preventing 
adverse cardiac remodeling. 
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Acute coronary artery blockage leading to prolonged ischemia and subsequent cardiomyocyte 
death (myocardial infarction; MI) initiates a reparative process in the heart that is associated with
the generation of regional infarct tissue composed predominately of fibrillar collagens. The 
surviving cardiomyocytes undergo eccentric hypertrophy, a process characterized by 
cardiomyocyte elongation with reduced diameter and impaired calcium handling, in particular 
decreased sarcoplasmic reticulum (SR)-mediated calcium uptake1. These cellular changes are 
fundamental to adverse cardiac remodeling, which manifests clinically as left ventricular (LV) 
wall thinning, dilation and reduced contractility2. Together with neurohumoral activation, 
adverse cardiac remodeling post-MI leads to the clinical syndrome of systolic heart failure (HF),
which despite optimized medical therapy is associated with extremely high mortality rates3.
Novel therapeutic strategies to preserve LV contractile function and limit adverse cardiac
remodeling are therefore urgently required to treat patients with MI and improve survival rates 
and quality of life. 
The Runx gene family (RUNX1, RUNX2 and RUNX3) encodes DNA-binding ?-subunits 
that partner core binding factor ?????????????????heterodimeric transcription factors4. RUNX 
proteins act as both activators and repressors of target genes in normal development and disease 
states4. To date, most research has focused on the role of RUNX1 in hematopoiesis owing to the 
frequent involvement of this gene in leukemic translocations4. By contrast, little was known 
about the role of Runx1 in the heart. This discrepancy is not surprising given that although 
Runx1 expression is reported in neonatal cardiomyocytes it decreases to minimal levels in adult 
cardiomyocytes5, 6. However, studies have demonstrated that Runx1 is re-activated in 
cardiomyocytes of the border zone (BZ) region adjacent to the infarct in both patients with MI 
and experimental animal models5, 7. Whether activation of Runx1 in adult cardiomyocytes 
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following MI is simply a marker of myocardial damage or actually plays a role in the progression 
of adverse cardiac remodeling is currently unknown. 
 We have now addressed this question by inducing MI in a mouse model where Runx1 has 
been specifically excised in cardiomyocytes. We report that these mice were protected against 
adverse cardiac remodeling following MI, with markedly preserved LV systolic function through 
improved SR-mediated calcium uptake. Re-activation of Runx1 following MI therefore plays a 
crucial role in excitation–contraction (EC) coupling and adverse cardiac remodeling and 
represents a new therapeutic target with the potential to limit progression to heart failure among
patients with MI.
Methods 
Detailed methods are provided in the Supplemental Material. The care and use of animals was in 
accordance with the UK Government Animals (Scientific Procedures) Act 1986 (ASPA). All 
animal procedures were approved by the University of Glasgow ethical review panel and 
licensed by the Home Office, UK (Project License Number 600/4503).
Coronary artery ligation 
Mice aged 10–12 wk (25–30g) underwent thoracotomy and left anterior descending (LAD) 
coronary artery ligation (permanent/temporary) using standard approaches.
Generation of cardiomyocyte specific Runx1 knock-out mice
Runx1fl/fl mice described previously8, were crossed with mice expressing tamoxifen-inducible 
Cre recombinase (MerCreMe) under the control of the cardiac specific alpha-myosin heavy chain 
(?MHC)9 to produce the relevant test and control cohorts (Supplemental Material). PCR of 
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genomic DNA, RNA isolation, cDNA synthesis, real-time qPCR analysis and immunoblotting 
are detailed in the Supplemental Material.  
Cardiac phenotyping
Echocardiography M-mode measurements were performed before and after LAD ligation and 
pressure–volume (PV) loop measurements recorded as a terminal procedure using the 
Scisense/Transonic small animal model PV system.
Histology 
Quantification of regional areas and infarct size was performed on picrosirius red/triphenyl 
tetrazolium chloride (TTC) stained histological sections using Image J and Adobe Photoshop. 
Cardiomyocyte size was assessed by AlexaFluor-594 conjugated wheat germ agglutinin (WGA; 
Invitrogen, UK) on adjacent sections. RNAscope using probes to specifically identify 
cardiomyocyte nuclei (pericentriolar material 1; PCM-1) and Runx1 was performed as detailed 
in the Supplemental Material. For each heart, positive (PPIB and POLR2A) and negative 
controls (bacterial dapB) were run (Supplemental Material Figure 1).
Calcium measurements 
Cardiomyocytes were isolated as previously described10, loaded with a calcium–sensitive
fluorophore (5.0?mol/L Fura-4F AM, Invitrogen) and perfused during field–stimulation (1.0Hz, 
2.0ms duration, stimulation voltage set to 1.5 x threshold). The Fura-4F fluorescence ratio 
(340/380nm excitation) was measured using a spinning wheel spectrophotometer (Cairn 
Research Ltd.; sampling rate of 5.0kHz) to measure the intra-cardiomyocyte [Ca2+]i. Cell-edge 
detection (IonOptix) was used to measure cell length. Data were analyzed offline as previously 
described11. Particular experiments utilized pretreatment (30min) and perfusion with the PKA 
inhibitor H89 (1?mol/L; Tocris Biosciences, Bristol UK) as previously described12.
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Adenoviral overexpression of Runx1 in vitro
Adenoviral vectors expressing either enhanced green fluorescent protein (GFP; Ad-GFP) or GFP 
and Runx1 in a bicistronic configuration (Ad-Runx1) were prepared and titered (see 
Supplemental Material). Cardiomyocytes isolated from adult New Zealand white rabbits (3kg) 
were cultured and transduced at a multiplicity of infection (MOI) of 100 for 24h.
Statistics 
Data were expressed as mean±SEM. Comparisons between MI and sham hearts were performed 
using the Student’s t test on raw data before normalization to percentage change. Comparisons 
between more than two groups were conducted on raw data using ANOVA. In cases where the 
two control groups were combined, statistics were performed on the pooled raw data of both 
control groups and compared with Runx1?/? mice using the Student’s t test. In experiments where 
multiple isolated cardiomyocyte observations (n) were obtained from each heart (N), we have 
firstly ensured normality of data distribution and then determined the differences between control 
and experimental mice using linear mixed modeling (IBM SPSS Statistics v22) as previously 
published13. 
Results 
Expression of Runx1 following MI 
Whilst Runx1 expression has previously been shown to increase at 3 wk post-MI it was unknown 
whether increased Runx1 expression occurred at a later time-point post-MI (e.g. 8 wk post MI). 
Furthermore, temporal changes in regional Runx1 expression have not previously been 
investigated. Runx1 expression was therefore quantified in hearts taken from C57BL/6J mice 
with MI induced by permanent coronary artery ligation and compared with C57BL/6J mice that 
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had a sham procedure but no coronary artery ligation. PV loop measurements confirmed 
C57BL/6J mice with MI had reduced systolic (Supplemental Material Figure 2A-C) and diastolic 
function (Supplemental Material Figure 2D&E) with a lower ejection fraction (Supplemental
Material Figure 2F-H).
Runx1 mRNA and protein levels
The levels of Runx1 mRNA increased by 2.5 fold in whole hearts 4 wk post-MI relative to 4 wk 
sham hearts (P<0.05; Supplemental Material Figure 2I). To determine the contribution of 
specific myocardial regions to the observed increase in Runx1 mRNA level, a separate cohort of 
sham and MI hearts were isolated and tissue isolated from four different regions (Supplemental
Material Figure 2J). Runx1 mRNA levels analyzed using the relative quantification (RQ) method 
increased by 5.1 fold and 1.8 fold in the infarct (INF) and BZ regions of 4 wk post-MI hearts 
relative to the respective right ventricular (RV) region (P<0.05; Supplemental Material Figure 
2K). No detectable change was noted in the Runx1 mRNA levels in the LV region at 4 wk post-
MI and no statistically significant regional differences were detected in the sham hearts 
(Supplemental Material Figure 2K).  
 The levels of Runx1 protein changed in line with levels of Runx1 mRNA (Supplemental
Material Figure 2L and M). Runx1 protein levels increased by 6.4 fold and 13.0 fold in the BZ 
and INF regions, respectively, relative to the LV region in 3 wk post-MI hearts (P<0.05).  
 The pattern of Runx1 mRNA expression was similar in 8 wk post-MI hearts, with an 
increase of 3.7 fold and 2.2 fold in the INF and BZ regions, respectively, relative to the 
corresponding RV region (P<0.05; Supplemental Material Figure 3). However, in contrast to 4 
wk post-MI hearts, the Runx1 mRNA levels were increased by 2.7 fold in the LV region relative 
to the RV region (P<0.05) at the 8 wk time point (Supplemental Material Figure 3).
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All of the observed regional changes in Runx1 mRNA expression occurred in the absence of any 
such changes in the RV region of MI hearts relative to sham hearts.
Expression of Runx1 in cardiomyocytes following MI 
We next delineated the spatial-temporal expression of Runx1 in cardiomyocytes from other 
cardiac cell types within different regions of the heart using RNAscope. Runx1 expression was 
found in 8-13% of cardiomyocytes and 5-7% of non-cardiomyocytes in the four regions (RV, LV 
and equivalent BZ and INF) of sham hearts (Figure 1A, B and C). Runx1 expression did not 
significantly differ from sham levels in the RV and LV regions at 1 and 14 day post-MI (Figure 
1A, B and C). However, Runx1 expression significantly increased to 43% and 44% of 
cardiomyocytes within the BZ and INF region respectively at 1 day post MI; a time where whole 
heart contractile dysfunction was also first observed (Figure 1A and B and Supplemental 
Material Figure 4). Furthermore, Runx1 expression significantly increased to 59% and 47% of 
cardiomyocytes within the BZ and INF region respectively at 14 day post MI (Figure 1A and B). 
With regards to other cardiac cell types, Runx1 expression significantly increased to 14% of non-
cardiomyocytes within the INF region at 1 day post MI (Figure 1A and C) and increased further 
to 35% and 26% of non-cardiomyocytes within the BZ and INF region respectively at 14 day 
post MI (Figure 1A and C). These data supported separate experiments which found an increased 
Runx1 level at 1 and 14 days post-MI in cardiomyocytes isolated from whole hearts and 
separated from other cell types as measured using rtqPCR data even though these data did not 
provide spatial resolution (Figure 1D).
Direct assessment of Runx1 function in cardiomyocytes. 
To directly determine the contribution of Runx1 in cardiomyocytes to reduced cardiac function,
we generated cardiomyocyte-specific Runx1-deficient mice using Cre-LoxP-based gene targeting 
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strategies (Supplemental Material and Supplemental Material Figure 5)9. Three groups of mice 
were generated: Runx1?/? mice (?MHC-MerCreMer:Runx1fl/fl); litter-mate Runx1fl/fl mice
controlling for the insertion of the LoxP sites8 and Runx1wt/wt mice controlling for insertion of the 
tamoxifen-inducible Cre recombinase (?MHC-MerCreMer:Runx1wt/wt)9. Cardiomyocyte-specific 
excision of Runx1 was induced in adult mice by a single i.p. injection of tamoxifen (40mg/Kg).
PCR of genomic DNA, rtqPCR and western blot analysis was performed on isolated 
cardiomyocytes and confirmed successful deletion of the Runx1 gene following injection with 
tamoxifen (Supplemental Material Figure 5). 
In vivo echocardiographic assessment of Runx1??? mice post-MI
In order to establish whether LV systolic function was altered in Runx1?/? mice post-MI we 
utilized M-mode echocardiography.   
Cardiac function 
MI was surgically induced in Runx1?/?, Runx1fl/fl and Runx1wt/wt mice 1 wk after tamoxifen
injection to all mice. Echocardiography was performed before MI and every 2 wk post-MI to 
assess cardiac contractile function (Figure 2A). As expected, cardiac systolic function (assessed 
by fractional shortening) decreased in both groups of control mice (Runx1fl/fl and Runx1wt/wt)
post-MI (Figure 2B). By contrast, Runx1?/? mice demonstrated a markedly preserved fractional 
shortening that was 158% of the control mice at 8 wk post-MI (39.5±0.7 vs. 24.9±1.9%; P<0.05; 
Figure 2A and B). Runx1?/? mice undergoing a sham procedure 1 wk post-tamoxifen injection 
demonstrated no change in fractional shortening over the equivalent 8 wk time course and were 
not significantly different from the Runx1?/? MI mice until the 8 wk time point (Figure 2B). The 
improved fractional shortening in Runx1?/? mice post-MI was the culmination of substantially
improved cardiac contraction as evidenced by the smaller LV internal diameter measured at 
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systole (LVIDs; Figure 2A and C), which was 77% of the two control groups post-MI (2.5±0.2 
vs. 3.3±0.1mm; P<0.05). Runx1?/? mice undergoing a sham procedure post-tamoxifen 
administration demonstrated no change in LVIDs over the equivalent 8 wk time course. The 
LVID measured at diastole (LVIDd) within the BZ region indicated that the hearts of both 
control and Runx1?/? mice post-MI dilated at this level of the myocardium albeit to a lesser 
degree in Runx1?/? mice (Figure 2D).
Cardiac structure 
As expected, LV posterior wall thickness during systole (LVPWs) measured at the level of the 
BZ of control mice (Runx1fl/fl and Runx1wt/wt) thinned after the 2 wk post-MI time point due to
the cardiac remodeling process (Figure 2E). By contrast, Runx1?/? mice displayed preserved wall 
thickness that was 164% of control mice (Runx1fl/fl and Runx1wt/wt) at 8 wk post-MI (2.07±0.14 
vs. 1.27±0.06mm; P<0.05; Figure 2E). Runx1?/? mice undergoing a sham procedure post-MI 
demonstrated no change in LVPWs over the equivalent 8 wk time course. The wall-thickness 
data were confirmed at diastole 8 wk post-MI (Figure 2F).
These data were confirmed in: (i) a separate blinded study (Supplemental Material Figure 
6A-E) where the operator was blinded to the animals undergoing surgery, echocardiography and 
analysis before MI and at 2 wk post-MI and (ii) at earlier time points at and before 1 wk post-MI 
(Supplemental Material Figure 7).
In vivo ventricular luminal volumes and ejection fraction in Runx1??? mice 2 wk post-MI
LV ventricular luminal volume of the Runx1?/? and control mice was assessed in vivo at 2 wk 
post-MI using pressure volume (PV) loops (Figure 2G). The end diastolic volume (EDV) in the 
Runx1?/? mice was reduced to 82% of that in the control mice (Runx1fl/fl and Runx1wt/wt), 
indicating a reduction in LV dilation (36.3±3.00 vs. 44.5±2.47 ?L; P<0.05; Figure 2G and H). 
 by guest on O
ctober 31, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.028911
11
The end systolic volume (ESV) in Runx1?/? mice was reduced to 54% of that of the control mice,
indicating a greater level of emptying of LV blood volume (12.9±2.98 vs. 23.7±2.51 ?L; P<0.05; 
Figure 2G and I). This leftward shift in the PV loop in the Runx1?/? mice resulted in an ejection 
fraction (EF) that was 138% of the control mice (66.3±5.69 vs. 48.0%±3.18%; P<0.05; Figure 
2G and J).
Histological assessment of Runx1??? mice 8 wk post-MI
Heart structure
We next investigated whether altered whole heart structure contributed to the preserved cardiac 
performance of Runx1?/? mice post-MI. Analysis of the different regions of the heart (Figure 3A) 
using picrosirius red staining of serial sections of hearts from Runx1?/? mice 8 wk post-MI 
showed that the mean two-dimensional whole heart area (RV+SEP+LV+INF) was 112% of 
control mice (Runx1fl/fl and Runx1wt/wt) post-MI (37.4±1.4 vs. 33.5±0.6mm2; P<0.05; Figure 3B). 
This increase in heart area was associated with the LV free wall (Figure 3A; dotted area), which 
in Runx1?/? mice post-MI was 127% of the control mice post-MI (11.0±0.8 vs. 8.7±0.4mm2;
P<0.05; Figure 3C). No change was detected in the RV wall area in Runx1?/? mice post-MI 
(Figure 3D) and therefore further investigation focused on the structure of the LV. 
LV wall thickness (measured at the level of the BZ; Figure 3A; arrows) in Runx1?/? mice 
post-MI was 127% of control mice post-MI (2.07±0.2 vs. 1.63±0.1mm; P<0.05; Figure 3E), a 
finding that supported the echocardiographic data (Figure 2E). No change was detected in the 
septal-wall thickness in Runx1?/? mice post-MI (Figure 3F) or overall heart weight (Figure 3G). 
Infarct thickness and fibrosis (Figure 3H&I) was not different in Runx1?/? mice post-MI versus 
control mice post-MI. Furthermore, infarct size (32.3?1.5% vs. 32.7?3.1 vs. 31.9?5% of LV; 
Runx1??? (N=5) vs. Runx1wt/wt (N=7) vs. Runx1fl/fl (N=5); P>0.05; Figure 3J) at 8 wks post-MI 
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(and the earlier time point of 24 h post-MI; Supplemental Material Figure 8A and B) was not 
different in Runx1?/? versus control mice, and therefore did not explain the preserved LV 
function observed in vivo (Figure 2B).
Cardiomyocyte size
To investigate why LV free wall thickness was preserved in Runx1?/? mice 8 wk post MI relative 
to the wall thinning observed in control mice post-MI (Figures 2E and F), the cardiomyocyte size 
in Runx1?/? mice 8 wk post MI was determined using wheat germ agglutinin staining (WGA). As 
expected, LV cardiomyocytes from control Runx1fl/fl and Runx1wt/wt mice 8 wk post-MI exhibited 
significant cell lengthening to 121% and 118% of Runx1?/? sham mice (111.7±3.8 vs. 108.8±3.7 
vs. 92.53±1.04?m; P<0.05; Figure 3K and L). However, cardiomyocyte elongation was absent in 
Runx1?/? mice at 8 wk post-MI (Figure 3K and L). An equivalent absence of cardiomyocyte 
lengthening was also observed in septal cardiomyocytes (Figure 3M). LV cardiomyocytes from 
control Runx1fl/fl and Runx1wt/wt mice 8 wk post-MI exhibited a significant decrease in cell 
diameter to 86% and 85% of Runx1?/? sham mice (15.91±0.83 vs. 15.88±0.75 vs. 18.86±0.37?m;
P<0.05; Figure 3N and O). However, cardiomyocyte cell diameter did not decrease in Runx1?/?
mice 8 wk post-MI (Figure 3O). LV cardiomyocytes from control Runx1fl/fl and Runx1wt/wt mice 8
wk post-MI exhibited a significant decrease in cardiomyocyte cross-sectional area to 79% and 
76% of Runx1?/? sham mice (350.6±23.9 vs. 338.2±22.6 vs. 440.0±11.5?m; P<0.05; Figure 3N 
and P). However, cardiomyocyte cell cross-sectional area did not decrease in Runx1?/? mice 8 wk 
post-MI (Figure 3P). No change in septal cardiomyocyte diameter was observed at 8 wk post-MI 
in any group (Figure 3Q).
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Calcium transients in Runx1??? mice 2 wk post-MI
Although increased fractional shortening paralleled increased wall thickness in Runx1?/? mice at 
8 wk post-MI (Figure 2B and E), we noted that wall thickness was not significantly different 
between the three groups at 2 wk post-MI. However, Runx1?/? mice still exhibited greater 
fractional shortening at this time point than was observed for the two control groups. To 
investigate this dichotomy, we isolated cardiomyocytes from hearts at 2 wk post-MI to 
characterize calcium handling. This was achieved by measuring the intracellular calcium
concentration ([Ca2+]i), focusing on electrically induced SR-mediated calcium release (calcium
transients) into the cytosol, which predominately determines the force of contraction. 
 Cardiomyocytes isolated at 2 wk post-MI were stimulated at 1.0 Hz to elicit calcium
transients and cell shortening (Figure 4A-C). The calcium transient peak (systolic [Ca2+]i) in 
Runx1?/? mice was 117% and 122% of the control (Runx1fl/fl and Runx1wt/wt) mice (582.8±36.1 
vs. 497.4±31.3 nM vs. 477.0±24.5nM [Ca2+]i; P<0.05; Figure 4B and D). The calcium transient 
minimum (diastolic [Ca2+]i) in Runx1?/? mice was 92% and 89% of the control (Runx1fl/fl and 
Runx1wt/wt) mice (137.8±4.5 vs. 149.8±6.3 vs. 155.1±6.8nM [Ca2+]i; P<0.05; Figure 4B and E). 
The changes in peak and minimum [Ca2+]i of Runx1?/? mice resulted in a calcium transient 
amplitude which was 128% and 138% of the control (Runx1fl/fl and Runx1wt/wt) mice (445.0±34.3 
vs. 347.5±29.0 vs. 321.9±20.7nM [Ca2+]i; P<0.05; Figure 4B and F). Furthermore, the time 
constant of calcium transient decay in the Runx1?/? mice was 65% and 55% of the control 
(Runx1fl/fl and Runx1wt/wt) mice (0.074±0.007 vs. 0.114±0.018 vs. 0.134±0.020s; P<0.05; Figure 
4B and G), suggesting an increased rate of removal of calcium from the cytosol. 
The increased calcium transient amplitude in Runx1?/? mice post-MI occurred in the 
absence of any significant changes in calcium entry or action potential duration (as measured 
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indirectly using the QT interval on the electrocardiogram or directly using voltage measurements 
on isolated cardiomyocytes at 2 wk post-MI) (Supplemental Material Figure 9).
Caffeine-induced calcium transients and cell shortening 
We hypothesized that the lowered time constant of decay detected in the Runx1?/? mice 2 wk 
post-MI might reflect either increased SR calcium uptake via SERCA or extrusion from the cell 
via the sodium calcium exchanger (NCX). To address this issue, we applied a rapid bolus of 
10mM caffeine at the end of the protocol to release all of the calcium from the SR into the 
cytosol. This approach enabled assessment of SR calcium content. 
The SR calcium content of the Runx1?/? mice was 135% and 118% of the control 
Runx1fl/fl and Runx1wt/wt mice, respectively (842.8±47.2 vs. 624.3±42.2 vs. 712.6±40.0nM 
[Ca2+]i; P<0.05; Figure 4H). SERCA-mediated calcium uptake is bypassed during application of 
10mM caffeine and cytosolic calcium removal occurs predominately via NCX. The activity of 
NCX, as assessed by the time constant of caffeine-induced calcium transient decay, was not 
different between the three groups (Figure 4I).
 The increased SR calcium content observed in Runx1?/? mice might reflect enhanced 
SERCA activity (KSERCA). Therefore, we measured the rate constant of decay of the caffeine-
induced calcium transient (which includes sarcolemmal efflux but not SR calcium uptake) and 
subtracted this value from that of the electrically stimulated calcium transient (which includes 
both SR calcium uptake and sarcolemmal efflux)14, 15. The KSERCA of the Runx1?/? mice was 
148% and 160% of control Runx1fl/fl and Runx1wt/wt mice (14.4±1.4 vs. 9.7±1.8 vs. 9.0±1.2s-1;
P<0.05; Figure 4J). To corroborate that the increased calcium transient amplitude of Runx1?/?
mice resulted in increased cell shortening, we performed edge-detection shortening 
measurements (Figure 4C). Cardiomyocyte shortening in Runx1?/? mice 2 wk post-MI was 156% 
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and 203% of the control Runx1fl/fl and Runx1wt/wt mice (7.5±0.9 vs. 4.8±0.6 vs. 3.7±0.4% of 
diastolic length; P<0.05; Figure 4C and K).
Effect of overexpressing Runx1 on calcium transient amplitude and SR calcium content in 
normal cardiomyocytes 
To further support the novel link between Runx1 and calcium handling in isolated 
cardiomyocytes, we performed a gain-of-function study by overexpressing Runx1 via
adenoviral-mediated gene transfer (Ad-Runx1) in isolated adult cardiomyocytes from normal 
hearts. The calcium transient amplitude in Ad-Runx1-transduced cardiomyocytes was 53% of 
cardiomyocytes transduced with the control adenoviral vector expressing green fluorescent 
protein (Ad-GFP) (70.5±8.3 vs. 133.4±30.7nM [Ca2+]i; P<0.05; Figure 4L and M). SR calcium
content in cardiomyocytes overexpressing Runx1 was 60% of the control cardiomyocytes 
(388.8±60.3 vs. 651.8±84.4nM [Ca2+]i; P<0.05; Figure 4N).
Expression of calcium handling proteins in Runx1?/? mice 2 wk post-MI
To investigate the mechanism by which SERCA activity is increased, we quantified the 
expression and phosphorylation levels of key calcium handling proteins involved in the control 
of SERCA-mediated calcium uptake in isolated cardiomyocytes 2 wk post-MI. 
 Levels of phospholamban (PLB), an inhibitory protein that regulates SERCA activity, 
were not significantly altered in the Runx1?/? mice (Figure 5A and B). By contrast, 
phosphorylation of PLB (which relieves SERCA inhibition and improves cardiac contractility) at 
the PKA-target residue Ser16 [P-PLB (Ser16)] was 331% of the control mice (Runx1wt/wt and 
Runx1fl/fl) (331.2±94.5 vs. 100±35.6% change; P<0.05; Figure 5A and C).
 Decreased levels of PKC indirectly enable enhanced phosphorylation of PLB and 
increase cardiac contractility16; however, no between-group differences were detected in the 
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levels of PKC (Figure 5D and E). Phosphorylation of PLB at the CaMKII-target residue 
threonine-17 ([P-PLB (Thr17)] in Runx1??? mice was 175% of the control mice (Runx1wt/wt and 
Runx1fl/fl) (175.0±22.9 vs. 100±8.2% change; P<0.05; Figure 5D and F). A possible regulator of 
phosphorylation of PLB is protein phosphatase 1 (PP1), which dephosphorylates PLB16. We 
found that expression of PP1 in Runx1??? mice was decreased to 28% of the control mice 
(Runx1wt/wt and Runx1fl/fl) post-MI (27.6±19.4 vs. 100±21.3% change; P<0.05; Figure 5G and H).
To confirm that the increased SERCA activity, SR calcium content and calcium transient 
amplitude observed in Runx1??? mice 2 wk post-MI (Figure 4) were PKA-mediated; we 
investigated the effect of the PKA inhibitor (H89) on calcium handling. Addition of H89 
completely blocked enhancement of all three parameters in the Runx1??? mice relative to the 
control Runx1wt/wt and Runx1fl/fl mice (Figure 5I–K).
Cardiac contractility in Runx1??? mice after ischemia with reperfusion
Reperfusion of a blocked coronary artery limits cell death following MI; this effect can be
achieved clinically via percutaneous coronary intervention. We therefore tested whether Runx1?/?
mice also maintain a preserved LV contractile function in an additional clinically relevant model 
of ischemia with reperfusion (I/R). 
The left anterior descending coronary artery was temporarily ligated in vivo for 45min 
followed by reperfusion and the Runx1?/? mice recovered for 8 wk. Fractional shortening was 
assessed using echocardiography before MI and weekly after the induction of MI with 
reperfusion. As expected, fractional shortening decreased in control Runx1fl/fl mice after 
reperfusion (Figure 6A and B). By contrast, Runx1?/? mice demonstrated markedly preserved 
fractional shortening, which was 154% of control Runx1fl/fl mice at 8 wk post-reperfusion 
(42.7±1.5 vs. 27.7±2.13%; P<0.05; Figure 6A and B). As with the animal model of permanent 
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coronary artery ligation, infarct size at 8 wks post-reperfusion (and the earlier time point of 24 h 
post-reperfusion) was not different in Runx1?/? versus control mice (Figure 6C and Supplemental 
Material Figure 8C and D). 
Discussion 
Runx1 has been most intensively studied in the hematopoietic system because its function is 
frequently corrupted in different subtypes of leukemia. Although it is known to have a role in 
lineage differentiation and tissue function in a range of other systems there is almost no 
information relating to its role in adult cardiomyocytes other than the observation that it can be 
reactivated following myocardial insult5, 7. Our novel study addressed a vital question; namely, is 
increased expression of RUNX1 post-MI merely a marker of ischemic damage or does it play a 
functional role in adult cardiomyocytes following MI? We provide new evidence that Runx1 has 
an important role in cardiomyocytes following MI. Reducing Runx1 function preserved cardiac 
contractility and prevented adverse cardiac remodeling, which suggests that targeting the actions 
of this gene could have important implications for patient survival post-MI. Importantly, this 
research transcends discipline boundaries as it not only widens the importance of Runx1 to other 
fields of medicine but also describes a novel function for this gene. 
 Our results provide the first detailed quantification of regional Runx1 expression in 
mouse heart tissue after myocardial infarction. At 4 wk post-MI, Runx1 mRNA was increased 
within the BZ myocardium and INF region which was sustained until at least 8 wk post-MI, at 
which time point Runx1 expression also increased within the remote LV myocardium. This is 
important given that changes in Runx1 expression at the mRNA and protein level are not 
restricted to rodent MI models but also occur in patients with MI5, 7. In separate experiments, we 
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were able to demonstrate that Runx1 expression is increased within the BZ and INF region post-
MI within the contractile elements of the heart i.e. the cardiomyocytes, as early as 1 to 14 days 
post-MI (Figure 1).  
 To determine the specific contribution of Runx1 in cardiomyocytes to reduced cardiac 
contractility, we generated a new tamoxifen-inducible cardiomyocyte-specific Runx1 deficient 
mouse with the hypothesis that these mice would demonstrate improved cardiac function. 
Induction of MI in control transgenic mice led to the expected LV wall thinning, cardiac dilation 
and reduced contractility 8 wk post-MI. However, all of these adverse cardiac remodeling 
parameters were absent or reduced in Runx1?/? mice at this time point. One possible explanation 
for the observed preservation of systolic function could have been a reduction in the infarct size 
of Runx1?/? mice given that infarct size correlates with systolic function17. However, Runx1?/?
mice exhibited preservation of geometric shape and contractility post-MI, with no difference in 
infarct size (at both early and late time points) or fibrosis versus the control mice. 
 To establish the mechanism underlying these notable findings, we first investigated 
cardiomyocyte size. Control mice demonstrated the expected cardiomyocyte lengthening and 
thinning (eccentric hypertrophy) at 8 wk post-MI1. However, these changes were absent in 
Runx1?/? mice. Such protection against eccentric hypertrophy at 8 wk post-MI seems highly 
likely to have afforded Runx1?/? mice protection from ventricular dilation and thinning, 
ultimately leading to preserved contractility. Nevertheless, at 2 wk post-MI, the wall thickness in 
Runx1?/? mice was comparable to that of control mice (as wall thinning in control mice had not 
yet begun) but contractile function was still dramatically improved. This finding indicated that 
prevention of wall thinning and dilation could not fully explain the preserved contractile function 
observed at 2 wk post-MI.
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 The above dichotomy led us to investigate calcium handling in cardiomyocytes isolated 
from Runx1?/? mice 2 wk post-MI, in particular electrically stimulated calcium release (the 
calcium transient) from the intra-cardiomyocyte calcium store (the SR) and subsequent cell 
shortening. Patients and animal models with MI typically exhibit calcium transients with lower 
amplitude and a slower rate of decline than control/healthy cardiomyocytes, an observation 
largely attributed to reduced SR-mediated calcium uptake via SERCA15. Runx1?/? mice exhibited 
increased calcium transient amplitude and reduced time constant of decline post-MI compared to 
control mice post-MI, resulting in an increase in cell shortening. The accompanying higher SR 
calcium content observed in Runx1?/? mice post-MI can explain the enhanced calcium transient 
amplitude18 since equalizing the SR calcium content with H89 resulted in a calcium transient 
equivalent to control.   
Analysis of the caffeine-induced calcium transient found no detectable change in NCX 
activity in Runx1?/? mice post-MI as compared to control mice post-MI. However, enhanced SR-
mediated calcium uptake via SERCA was observed in the Runx1?/? mice. SERCA activity is a 
major determinant of the SR calcium content. Furthermore, this pump is regulated predominately 
by the inhibitory protein phospholamban (PLB). Although expression of PLB was not altered in 
Runx1?/? mice post-MI, we explored some of the proteins that regulate PLB activity16.
PLB-mediated inhibition of SERCA is balanced by phosphorylation by PKA and 
CaMKII (which relieves SERCA inhibition) and dephosphorylation by PP1 (which returns PLB 
to its inhibitory state16). We found that ventricular cardiomyocytes from Runx1?/? mice exhibited
increased PKA-mediated phosphorylation of PLB possibly as a result of reduced levels of PP1. 
These mechanistic data suggest that PLB phosphorylation stimulates SERCA activity in Runx1?/?
mice post-MI, and leads to an increased SR calcium content, which in turn increases electrically 
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induced SR-mediated calcium release and doubles cardiomyocyte contraction. Our proposed 
mechanism was supported by complete blockage of the enhanced calcium transient in 
cardiomyocytes from Runx1?/? mice 2 wk post-MI by inhibition of PKA. The enhanced rate of 
removal of calcium from the cytosol following increased SERCA activity is sufficient to reduce 
the end diastolic [Ca2+]i, which not only improves whole heart relaxation but may also limit the 
stimulation of hypertrophic factors1.  
Previous studies strongly support our proposed mechanism that the effect of Runx1 on 
SR function is a major contributor to the beneficial effects observed in Runx1?/? mice post-MI. 
Decreased SR function has been demonstrated among patients with HF15 and enhanced SR-
mediated calcium cycling markedly preserved contractility, reduced adverse cardiac remodeling 
and delayed progression to heart failure at levels not dissimilar from those observed in the 
current study16, 19.  
 The key findings of our study will likely initiate further research into the beneficial 
effects of decreasing Runx1 expression in alternative animal models of cardiac disease. As 
testament to this goal, we found that Runx1?/? mice are protected from adverse cardiac 
remodeling in a separate clinically relevant surgical model. In this model, the blocked coronary 
artery was subsequently unblocked after a period of ischemia, as would be the case for patients 
undergoing percutaneous coronary intervention. These additional data further support our study 
and the translational potential of this new target.  
 Although our strategy did not result in inactivation of the Runx1 gene in all 
cardiomyocytes, we postulate that cardiac function improves when only a subset of 
cardiomyocytes benefits from better Ca2+ handling after inactivation of Runx1. Since it is more 
feasible in a clinical setting to suppress genes in a subset of cardiomyocytes rather than in all 
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cells, we think Runx1, or targets showing a similar potency, are particularly attractive for 
therapeutic interventions.
In conclusion, we have demonstrated for the first time that Runx1 modulates cardiac SR 
calcium uptake and contractile function. Reducing Runx1 function drives increased contractility 
post-MI, thereby preserving LV systolic function and preventing adverse cardiac remodeling. 
Clinical studies clearly demonstrate that preserving cardiac contractility and protecting against 
adverse cardiac remodeling are key factors to limiting progression from MI to heart failure2.
Identification of a new therapeutic target that achieves this objective is urgently required. To this 
end, we envisage that Runx1 will be exploited in future basic and translational studies to limit 
progression of patients with MI to heart failure, thereby improving survival rates and quality of 
life. 
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Figure Legends
Figure 1. Runx1 expression in WT C57BL/6 mice post-MI. (A) Typical images of regional 
heart sections with RNA in situ hybridization (using RNAscope®). Regions examined were right 
ventricle (RV), left ventricle (LV), border zone (BZ) and infarct (INF) in 1 day (middle; n=3)
and 14 day (bottom; n=3) post-MI and equivalent regions in sham hearts (top; n=5). Probes for 
Runx1 (pink) and PCM-1 (cardiomyocyte specific; brown) were used; colored punctate dots 
represent positive staining (arrows). Scale bar (10?m); magnified insert image (5?m). (B) Mean 
quantification of cardiomyocytes (PCM-1+) and (C) non-cardiomyocytes PCM-1-) with Runx1 
positive staining as a % of the total number of cardiomyocytes or non-cardiomyocytes 
respectively (*P<0.05, 1 day post-MI vs. sham; #P<0.05, 14 day post-MI vs. sham - Student’s t-
test). (D) Runx1 expression as measured by rtPCR in cardiomyocytes isolated from whole sham 
(n=17) and 1 day (n=8), 7 day (n=6) and 14 day (n=3) post-MI hearts (ANOVA). Stock 
(C57BL/6J; n=4) mice were included to show that there was no detectable difference with sham 
hearts (ANOVA).  
Figure 2. Cardiac function in Runx1?/? mice. (A) Echocardiography (scale:x=0.1s;y=2mm). 
(B) 8 wk echocardiographic data for fractional shortening (FS) and (C) LV internal diameter 
(LVID) at systole (LVIDs), (D) LVID at diastole (LVIDd), (E) LV posterior wall thickness at 
systole (LVPWs) and (F) LVPW thickness at diastole (LVPWd). (Runx1fl/fl MI and Runx1wt/wt MI 
combined [n=11], Runx1?/? MI [n=9] and Runx1?/? sham [n=5]), (ANOVA). #P<0.05=Runx1???
MI mice versus Runx1??? sham mice. *P<0.05=Runx1??? MI mice versus control Runx1fl/fl MI 
and Runx1wt/wt MI mice combined. (G) Pressure–volume (PV) loops of Runx1wt/wt and Runx1?/? 2 
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wk post-MI. (H) Mean PV data 2 wk post-MI End diastolic volume (EDV), (I) End systolic 
volume (ESV) and (J) Ejection fraction (EF) (Runx1fl/fl MI and Runx1wt/wt MI combined [n=11], 
Runx1?/? MI [n=8]), *P<0.05 Student’s t-test.
Figure 3. Runx1?/? mice cardiac structure 8 wk post-MI. (A) Picrosirius red stained hearts 
(BZ,border zone; LV,left ventricle; INF,infarct; RV,right ventricle; SEP,septum; scale: 1mm).
Mean (B) area of whole heart (all regions), (C) LV, (D) RV and (E) LV wall thickness at BZ
region, (F) septum wall thickness at BZ region level, (G) heart weight to body weight ratio, (H)
infarct thickness, (I) LV fibrosis and (J) infarct size (Runx1fl/fl MI and Runx1wt/wt MI combined 
[n=12], Runx1?/? MI [n=5]; *P<0.05), Student’s t-test. (K) Wheat germ agglutinin (WGA) 
staining of LV cardiomyocytes (longitudinal) of Runx1fl/fl MI (top) and Runx1?/? (bottom) post-
MI (scale bar:25mm). (L) Mean LV cardiomyocyte length (Runx1?/? sham [n=55 
cardiomyocytes,n=3 hearts], Runx1fl/fl MI [n=122 cardiomyocytes,n=6 hearts], Runx1wt/wt MI
[n=109 cardiomyocytes from n=6 hearts], Runx1?/? MI [n=102 cardiomyocytes,n=6 hearts]), 
*P<0.05 linear mixed modelling. (M) Mean SEP cardiomyocyte length (Runx1?/? sham [n=29
cardiomyocytes,n=3 hearts], Runx1fl/fl MI [n=82 cardiomyocytes,n=6 hearts], Runx1wt/wt MI
[n=84 cardiomyocytes,n=6 hearts], Runx1?/? MI [n=64 cardiomyocytes,n=6 hearts]. (N) WGA
staining of LV cardiomyocytes (transverse) of Runx1wt/wt MI (Left) and Runx1?/? MI (Right) 
(scale bar:25mm). (O) Mean LV cardiomyocyte diameter (Runx1?/? sham [n=449 
cardiomyocytes,n=3 hearts), Runx1fl/fl MI [n=811 cardiomyocytes,n=6 hearts], Runx1wt/wt MI
[n=897 cardiomyocytes,n=6 hearts], Runx1?/? MI [n=878 cardiomyocytes,n=6 hearts]). (P) Mean 
LV cardiomyocyte cross sectional area (Runx1?/? sham [n=403 cardiomyocytes,n=3 hearts), 
Runx1fl/fl MI [n=714 cardiomyocytes,n=6 hearts], Runx1wt/wt MI [n=785 cardiomyocytes,n=6 
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hearts], Runx1?/? MI [n=699 cardiomyocytes,n=6 hearts]). (Q) Mean SEP cardiomyocyte 
diameter (Runx1?/? sham [n=238 cardiomyocytes,n=3 hearts], Runx1fl/fl MI [n=465 
cardiomyocytes,n=6 hearts], Runx1wt/wt MI [n=454 cardiomyocytes,n=6 hearts], Runx1?/? MI
[n=452 cardiomyocytes,n=6 hearts]), *P<0.05 linear mixed modelling. 
Figure 4. Excitation–contraction coupling in Runx1?/? mice 2 wk post-MI. (A) Protocol (B)
Typical calcium (Ca2+) transients and (C) cell shortening. Mean Ca2+ transient: (D) peak, (E)
minimum and (F) amplitude (Runx1fl/fl MI [n=25 cardiomyocytes,n=3 hearts], Runx1wt/wt MI
[n=28 cardiomyocytes,n=4 hearts], Runx1?/? MI [n=28 cardiomyocytes,n=3 hearts]; *P<0.05 
Runx1?/? MI vs. Runx1fl/fl MI and Runx1wt/wt MI combined, linear mixed modelling). (G) Mean 
time constant of Ca2+ transient decay. (H) Mean caffeine-induced Ca2+ transient amplitude. (I)
Mean time constant of decay for caffeine-induced Ca2+ transient amplitude. (J) Mean sarco–
endoplasmic reticulum calcium transport ATPase (SERCA) activity. (K) Mean fractional 
shortening (Runx1fl/fl MI [n=27 cardiomyocytes,n=3 hearts], Runx1wt/wt MI [n=27 
cardiomyocytes,n=4 hearts], Runx1?/? MI [n=23 cardiomyocytes,n=3 hearts]). (L) Ca2+
transients from cardiomyocytes transduced with Ad-GFP or Ad-Runx1. Mean: (M) Ca2+
transient peak; Ad-GFP (n=16 cardiomyocytes,n=6 hearts) and Ad-Runx1 (n=22 
cardiomyocytes,n=6 hearts), *P<0.05 linear mixed modelling (N) Caffeine-induced Ca2+
transient amplitude; Ad-GFP (n=13 cardiomyocytes,n=6 hearts) and Ad-Runx1 (n=19 
cardiomyocytes,n=6 hearts), *P<0.05 linear mixed modelling. 
Figure 5. Phospholamban regulation in isolated cardiomyocytes from Runx1?/? mice 2 wk 
post-MI. (A) Western blot of phospholamban (PLB), phosphorylation of PLB at serine-16 [P-
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PLB (Ser16)] and pan-actin loading control. Percentage change in protein for (B) PLB and (C)
P-PLB (Ser16/total PLB) (Runx1?/? MI [n=5 hearts] versus Runx1wt/wt and Runx1fl/fl MI [n=5 
hearts]), *P<0.05 Student’s t-test. (D) Western blot of PKC, PLB, and PLB phosphorylation at 
threonine-17 (P-PLB (Thr17)). Percentage change in protein for (E) PKC and (F) P-PLB 
(Thr17/total PLB) (Runx1?/? MI [n=5 hearts] versus Runx1wt/wt MI and Runx1fl/fl MI [n=9 hearts]), 
*P<0.05 Student’s t-test. (G) Western blot of protein phosphatase 1 (PP1). (H) Percentage
change in PP1 (Runx1?/? MI [n=5 hearts] versus Runx1wt/wt MI and Runx1fl/fl MI [n=9 hearts]). (I, 
J, K) Mean SERCA activity, caffeine–induced calcium transient amplitude and calcium transient 
amplitude data from Figure 4 compared to mean data obtained from 2 wk post-MI isolated 
cardiomyocytes with H89 (hatched white column; Runx1wt/wt MI and Runx1fl/fl MI+H89 [n=16 
cardiomyocytes,3 hearts] and hatched red column; Runx1?/? MI+H89 [n=15 cardiomyocytes, 3 
hearts]), *P<0.05 Student’s t-test.
Figure 6. Runx1?/? mice after ischemia with reperfusion (I/R). (A) Echocardiographic images 
(scale:x=0.1s;y=2mm). (B) Mean echocardiographic fractional shortening data of Runx1fl/fl I/R
(n=9) and Runx1?/? I/R (n=8) [*P<0.05], Student’s t-test. (C) Mean infarct size (Runx1fl/fl I/R
[n=9] and Runx1?/? I/R [n=7]), Student’s t-test.
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SUPPLEMENTAL MATERIAL 
  
2 
 
Requests by researchers to access the data, analytic methods, and study materials for the 
purposes of reproducing the results or replicating procedures can be made to the 
corresponding author who manages the information. 
Coronary artery ligation 
Mice aged 10–12 wk (25–30 g) were anesthetized by inhalation of 4% isofluorane gas 
(Isoflo, Abbott Laboratories, USA) delivered in O2 at 1.5 L/min. Animals were given 
preoperative analgesia of 5 mg/kg carprofen (Rimadyl, Pfizer Animal Health, U.) and 0.1 
mg/kg buprenorphine (Vetergesic, Reckitt Benckiser Healthcare Ltd, UK) i.p. delivered in 0.4 
mL of sterile saline. Mice were endotracheally intubated and maintained with artificial 
ventilation at 120 breaths/min with a tidal volume of 120 µL on 1% isofluorane in 0.5 L/min 
O2. Mice were positioned in a left lateral oblique position. The skin was incised perpendicular 
to the sternum in parallel with the ribs 5 mm proximal to the xyphoid process. Underlying 
muscles were carefully retracted to expose the fifth intercostal space beneath. The 
intercostal muscle was cut using an electrocautery pen and the ribs retracted to expose the 
heart. The pericardial sac was opened and removed to provide access to the left anterior 
descending (LAD) coronary artery which was then ligated with 0.3 metric nylon (W2829 
Ethilon, Johnson & Johnson, UK) 1.5 mm distal to the left atrial appendage. Three sutures 
were evenly pre-placed along the ribs using 0.7 metric non-absorbable prolene (W8711, 
Johnson & Johnson, UK). The lungs were reinflated until the pre-placed sutures were tied. 
The thoracic muscles were returned to their original position and skin closed with 0.7 metric 
absorbable vicryl (W9575, Johnson & Johnson, UK). Animals that underwent the sham 
procedure had a thoracotomy without LAD ligation. Temporary LAD ligation (I/R model) was 
achieved by using a piece of polyethylene tubing (PE-10; outer diameter 0.61 mm) against 
which the coronary artery was tied temporarily (45 min) and then subsequently released by 
removal of the tubing. Post-operatively, animals were given buprenorphine orally for 3 days. 
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RNA isolation, cDNA synthesis and real-time qPCR analysis 
Total RNA was extracted from heart tissue using the miRNeasy Mini Kit (Qiagen, UK) with 
DNase I treatment (Qiagen, UK). 1 µg of RNA was then reverse transcribed to cDNA with 
Omniscript reverse transcriptase, dNTPs, RNase inhibitors and oligo dT primers (Omniscipt 
Reverse Transcription kit, Qiagen, UK). Real-time quantitative PCR (qPCR) reactions were 
run using cDNA with a Runx1 quantitect primer assay (Amplicon length-120bp, 
Mm_Runx1_1_SG QuantiTect Primer Assay [QT00100380], Qiagen, UK) and SYBR green 
mastermix (Applied Biosystems, UK) or with a Runx1 Taqman Gene Expression Assay 
(Amplicon length 81bp, Mm01213404_m1) and Taqman Univeral Mastermix Mix II, no UNG 
(both ThermoFisher Scientific, UK) in a 20 µL final volume or 10 µL final volume respectively 
with the following cycling conditions: hold for 2 min at 50°C followed by 10 min at 95°C to 
heat-start the Taq polymerase enzyme, then 40 cycles of 95°C for 10 min, 60°C for 1 min. 
Relative mRNA levels were analysed using comparative Ct calculations; either 2-ΔΔCt 
(regional comparisons relative to RV region) or 2-ΔCt (whole heart or cardiomyocytes) 
normalised to Gapdh (whole heart; Eurofins MWG Operon, Germany), or Gapdh Taqman 
Gene Expression Assays (Amplicon length 109 Mm99999915_g1, ThermoFisher Scientific, 
UK) or Peptidylprolyl Isomerase B; PPIB (isolated cardiomyocytes).  
 
Generation of mice with conditional cardiomyocyte-specific gene excision of Runx1 
We generated cardiomyocyte-specific Runx1-deficient mice using standard Cre-LoxP-based 
gene targeting strategies (Supplemental Material Figure 5). This approach utilized mice with 
LoxP sites flanking exon 4 of the Runx1 gene (Runx1fl/fl) and mice with the cardiac-specific 
alpha-myosin heavy chain (MHC) promoter directing expression of a tamoxifen-inducible Cre 
recombinase (MerCreMer) to adult cardiomyocytes1. Cardiomyocyte-specific excision of 
Runx1 was induced in adult mice by a single i.p. injection of tamoxifen (40 mg/Kg) to prevent 
cardiac dysfunction arising from repeated injections2. 
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Genomic PCR was performed to determine the specificity of the Runx1 gene disruption 7 d 
after injection with tamoxifen (Supplemental Material Figure 5A–C). Excision of exon 4 
(denoted by the PCR product presenting at approximately 310 bp following gel 
eletrophoresis) was clearly present in all male and female mice. However, this size PCR 
product was absent in control Runx1fl/fl mice, which instead produced only a 275 bp PCR 
product, denoting insertion of the LoxP sites. Control Runx1wt/wt mice exhibited only a 203 bp 
PCR product representing an unaltered Runx1 gene as expected. To determine the extent to 
which the Runx1 gene had been excised from cardiomyocytes, PCR of genomic DNA was 
performed on both: (i) whole hearts and (ii) cardiomyocytes that had been separated from 
other cell types by plating and short term culture or by FACS (Supplemental Material Figure 
5C). Isolated cardiomyocytes exhibited an increased ratio of the excised PCR product (310 
bp) to the combined excised (310 bp) and LoxP product (275 bp) indicating approximately 
~50% Runx1 gene excision (Supplemental Material Figure 5C).  
Whilst the mRNA Runx1 levels were significantly reduced in whole heart tissue taken from 
the right (RV) and left ventricle (LV) of Runx1Δ/Δ mice compared to control mice (Runx1wt/wt 
and Runx1fl/fl) 4 wk post-MI, this was not the case in the border zone (BZ) and infarct (INF) 
regions reflecting the increased number of non-cardiomyocytes in these regions post-MI 
(Supplemental Material Figure 5D). 
At 2 wk post-MI, mRNA Runx1 levels (relative to the house keeper gene Peptidylprolyl 
Isomerase B; PPIB) in cardiomyocytes isolated from Runx1Δ/Δ mice were 61% of the control 
mice (Runx1fl/fl) (0.055±0.006 vs. 0.090±0.012 (2-Δct); P<0.05; Supplemental Material Figure 
5E) and Runx1 protein levels in cardiomyocytes isolated from Runx1Δ/Δ mice were 48% of 
the control mice (Runx1wt/wt and Runx1fl/fl) (47.6±9.6 vs. 100±3.84% change; P<0.05; 
Supplemental Material Figure 5F) indicating that protein and mRNA expression correlates 
with the level of gene excision in these cells.  
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PCR of genomic DNA 
Mice were killed by the schedule one procedure. Hearts were removed and perfused via the 
aorta with saline solution to wash out the blood before being snap frozen in liquid N2 and 
stored at –80˚C. The tissue was homogenized with the TissueLyser system (QIAGEN) using 
a stainless steel bead in each sample. Tissue was disrupted mechanically in proprietary lysis 
buffer (Illustra Nucelon Genomic DNA Extraction kit, GE Healthcare) until no visible pieces 
of tissue remained (~2 min at 25 oscillations/s). Lysates were incubated for at least 3 h with 
proteinase K at 50˚C. DNA was extracted according to the manufacturer’s instructions. 
Primers used were as described by Chen et al. 3: Runx1 forward primer WT and floxed 
alleles (Ex4Int – F563) 5’- CCC ACT GTG TGC ATT CCA GAT TGG -3’; Runx1 reverse 
primer for WT and floxed alleles (Ex4 – R837) 5’- GAC GGT GAT GGT CAG AGT GAA GC -
3’; and Runx1 reverse primer for deleted floxed allele (Int3-2) 5’- CAC CAT AGC TTC TGG 
GTG CAG -3’. Herculase II Fusion DNA polymerase (Agilent) was used under the following 
stepwise cycling conditions: 
1  95°C 1 min  
2  95°C 20 s 
3  58°C 20 s 
4  68°C 1 min 
5  Repeat steps 2–4, 30 times 
6  68°C 4 min 
7  12°C hold 
 
RNAscope® assay 
RNA in situ hybridization was performed using the RNAscope® duplex kit (Red/Brown) 
(Advanced Cell Diagnostics) on the Leica Bond Rx Autostainer to detect Runx1 and PCM-1 
using mouse-specific probes (Advanced Cell Diagnostics) on formalin fixed paraffin 
embedded (FFPE) mouse hearts. PCM1 has been shown to be 95-99.9% specific to 
cardiomyocytes furthermore, cardiomyocytes could be identified morphometrically by their 
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elongated nucleus and/or the presence of surrounding muscle striations4-6. Adult mouse 
hearts at 1 and 14 day post-MI and SHAM FFPE were cut at 4 μm and placed in an oven 
60°C for 1 h. The duplex staining protocol was performed following the manufacturer’s 
(Advanced Cell Diagnostics) strict guidelines. For each heart, positive (PPIB and POLR2A) 
and negative controls (bacterial dapB) were run (Supplemental Material Figure 1). The 
images were visualized on a brightfield Evos Cell Imaging microscope. Cells were 
considered to be positive if at least one brown (PCM-1) or red (Runx1) punctate dot was 
present within the nuclei - a single punctate dot representing a single mRNA transcript7. 
Cells were manually counted for quantification as previously described7 taking three 
representative images per region of the heart on mid-heart sections where the aorta is 
confluent with the LV chamber. 
 
Pressure–volume loop measurements 
Pressure–volume (PV) loop measurements were recorded using the Transonic ADV500 
small animal model PV measurement system or a Scisense PV loop system and a 1.2 F 4.5 
mm spaced PV admittance catheter (FTH-1212B-4517, Scisense, UK) as previously 
described8. Mice were anesthetized in a pre-filled induction chamber with 4% isofluorane 
gas (Isoflo, Abbott Laboratories, USA) delivered in O2 at 1.5 L/min. Mice were 
endotracheally intubated and maintained with artificial ventilation at 120 breaths/min with a 
tidal volume of 120 µL. Isofluorane concentration was gradually reduced to 1.5% during the 
procedure and maintained at this level for the duration of the measurements. The 
temperature was maintained at 37ºC by a homeothermic monitoring system (Harvard 
Apparatus, UK). A longitudinal incision was made in the center of the neck and the right 
carotid artery dissected free of the surrounding tissue. A small incision was made in the 
vessel and the catheter inserted into the vessel and advanced into the left ventricle of the 
heart. Steady state readings were then taken for 15 min. Data were recorded in the 
Labscribe software via a four-channel analog-to-digital converter. Data were analyzed offline 
by averaging the final 2 min of steady state recording. 
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Echocardiography 
Mice were anesthetized as for pressure–volume loop measurements and maintained via 
facemask on 0.5-1% isofluorane in 1.0 L/min O2.   
 
Histology 
Hearts from killed animals were fixed for a minimum of 24 h in 10% neutral buffered formalin 
(CellPath, UK) after which time they were embedded into a wax block for sectioning. Each 
heart was sliced parallel to the long axis every 200 µm to produce 4 µm serial sections. At 
every 200-µm interval, picrosirius red was used to stain collagen until the mid-point depth of 
the heart (defined by the largest ventricular cavity size and confluence of the LV chamber 
with the aorta). Quantification of regional areas and infarct size was performed on each 
section using Image J and Adobe Photoshop CC 2015 and mean data per heart were 
generated as described in previous studies9. The point at which the infarct region became 
50% of muscle and 50% of collagen (as determined using picrosirius red staining) was 
denoted as the BZ in histological sections. Infarct thickness was defined and measured as 
the distance between the endocardium and epicardium of the infarcted myocardium. This 
was performed using three lines drawn perpendicular to the curvature of the ventricular wall 
and the distance measured with ImageJ on each histological section. Cardiomyocyte size 
was assessed by staining adjacent sections at the level of the middle of the heart with 
AlexaFluor-594 conjugated wheat germ agglutinin (WGA; Invitrogen, Paisley, UK). Briefly, 
de-waxed and rehydrated sections were boiled in sodium citrate buffer for 10 min, followed 
by blocking in 1% BSA/PBS with 5% goat serum for 1 h. Sections were then incubated with 
10 µg/mL WGA for 1 hr at room temperature in the dark. Sections were mounted in ProLong 
Gold with DAPI (Invitrogen, Paisley, UK). Confocal imaging was used to produce an image 
of the LV and septum from each heart. A digital grid was placed on the image using ImageJ 
and grid intersections determined which cardiomyocytes where then chosen for 
measurement of cell length, diameter (perpendicular to centre of longest axis) and cross-
sectional area (thus avoiding cell selection bias). 
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Infarct size at 24 h post-MI and I/R injury. 
Infarct size in the mouse MI model was determined using triphenyltetrazolium chloride (TTC) 
(dissolved at 1% in a phosphate buffer for 15 min [37°C]) to detect viable tissue in x5 
transversely cut myocardial slices per heart. In the mouse I/R model, the area at risk (AAR) 
and infarct size was measured using previously published protocols10 whereby 1% Evans 
blue delineated the area not at risk, TTC the viable tissue and infarct region white. Heart 
slices were then placed into 10% neutral buffered formalin for 20 min at room temperature. 
Digital photographs of the myocardial sections from each heart were laid onto a white 
background and whole photograph white balanced against the background using Adobe 
photoshop. The number of pixels of each region was counted using Image J (National 
Institute of Health, Maryland, USA) and expressed as relative %. 
 
Adult cardiomyocyte isolation 
Hearts were removed and the coronary arteries perfused via the aorta at 4.0 mL/min (37°C) 
with a Modified Isolation Krebs–Henseleit (MIKH) solution for 4 min. The composition of 
MIKH (in mmol/L) was: NaCl (120.00), KCl (5.40), HEPES (20.00), NaH2PO4 (0.52), 
MgCl26H2O (3.50), taurine (20.00), creatine (10.00), glucose (11.10). The pH was adjusted 
to 7.4 with NaOH. Perfusion of hearts with MIKH was followed by perfusion with MIKH 
containing 1.0 mg/mL of type I collagenase (Worthington Biochemical) and 0.1 mg/mL of 
type XIV protease (Sigma-Aldrich). After ~6 min, the enzymes were removed and the heart 
perfused with MIKH containing 0.7% BSA (Sigma-Aldrich) but no enzymes for a further 4 
min. The left ventricular free wall was then cut into strips and mixed to yield a single-cell 
suspension in MIKH containing 0.7% BSA. The calcium concentration in solution ([Ca2+]o) 
was raised in this suspension via stepwise increments until 1.0 mmol/L was reached. 
 
Immunoblotting 
Isolated cardiomyocytes were lysed in radioimmunoprecipitation assay (RIPA) buffer. The 
composition of the RIPA buffer (in mmol/L) was: Tris (20), NaCl (150), EDTA (5), EGTA (5), 
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DTT (1) plus 1.0% Triton X-100 and 0.5% deoxycholate. MI tissue samples in Supplemental 
Material Figure 2 were disrupted in extraction buffer (0.1 M Tris–HCl, 0.01 M EDTA, 0.04 M 
DTT, 10% SDS, pH 8.0) using an ultrasonic device. Protease inhibitors added (in mmol/L) 
were: Na pyrophosphate (2.5), β-glycerophosphate (1.0), Na3VO4 (1.0), PMSF (1.0), NaF 
(2.0), plus 10 µg leupeptin, one tablet of a protease inhibitor cocktail (Complete Mini, Roche, 
Germany) and one tablet of phosphatase inhibitor (Phos-stop, Roche, Germany) per 10 mL 
buffer. The buffer was adjusted to pH 7.4. Lysates were assayed for protein concentration 
using the bicinchoninic acid assay. BSA was used to produce a standard curve. Samples 
were mixed with β-mercaptoethanol as the reducing agent and a loading dye before heating 
at 99˚C for 90 s. The lysates were loaded at a concentration of 10 µg per well into 4–12% 
Bis-tris gels (NuPAGE, Life Technologies, UK) with 4 µg of lysed thymus tissue as a positive 
control. Electrophoresis conditions were 75 V for 10 min followed by 165 V for 60–90 min. 
Protein was transferred to 0.45 µm pore size nitrocellulose membranes (Life technologies, 
UK). 
 
Membranes were incubated overnight at 4˚C with primary antibodies against: PLB A2 
(1:1000; MA3-922, Pierce), Runx1 (1:500; ab35962, AbCam), p-PLB Ser16 and p-PLB 
Thr17 (1:1000; A010-12 and A010-13, Badrilla), PKCα (1:200; sc-8393, Santa Cruz), PP1 
(1:200; sc-7482, Santa Cruz). Pan-actin (1:1000; 4968s, Cell Signalling) or Red Alert 
Western blot stain (Merck Millipore) were used as loading controls. Secondary antibodies 
were donkey anti-mouse IRDye 800 CW and donkey anti-rabbit IRDye 680RD (1:10000; 
926-32212 and 926-68073, Li-Cor). Western blots were visualized and quantified using a LI-
COR fluorescence imager and LI-COR or Quantity One analysis software. Figure 5A, 5D 
and 5G are separate blots but have been cut and probed separately for each different target. 
Same lanes were used for Runx1wt/wt MI mice in Figure 5D hence the actin signal is common 
to both PKC and PLB. 
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Epifluorescence measurements of field stimulated calcium transients 
Isolated cardiomyocytes (1.8 mmol/L [Ca2+]o) were loaded with calcium–sensitive 
fluorophore (5.0 µmol/L Fura-4F AM, Invitrogen). Cardiomyocytes were incubated in MIKH 
for 30 min for de-esterification in a cell bath (Cell Microcontrols) followed by superfusion with 
MIKH at 37°C and field–stimulation (1.0 Hz, 2.0 ms duration, stimulation voltage set to 1.5 x 
threshold). Caffeine (10 mmol/L, 20 s; without field stimulation) was applied before the 
protocol. Field-stimulation was started after 10 s of perfusion with MIKH and sustained for 
120 s before application of a second caffeine bolus at the end of the protocol. The Fura-4F 
fluorescence ratio (340/380nm excitation; R340/380nm) was measured using a spinning wheel 
spectrophotometer (Cairn Research Ltd.; sampling rate of 5.0 kHz) to measure the intra-
cardiomyocyte [Ca2+]i. Cell-edge detection (IonOptix) was used to measure cell length. Data 
were analyzed offline. The mean Fura-4F fluorescence ratio was obtained by averaging 12 
steady state transients (Origin) and converted to [Ca2+]i as previously described11. Particular 
experiments utilized pretreated (30 min) and perfusion with the PKA inhibitor H89 (1 µmol/L; 
Tocris Biosciences, Bristol UK) as previously described12. 
 
Determination of the in vivo electrocardiogram (ECG) in Runx1Δ/Δ and control mice 2 
wk-post-MI.  
Mice were anaesthetised and maintained at 1 % isoflurane in 1 L/min O2. ECG was recorded 
with an IX-228/S data acquisition unit and LabScribe2 software (iWorx) using 3 electrodes, 
placed subcutaneously in the right forelimb, left forelimb and right hindlimb. The ECG was 
recorded for 5 min, traces analysed with Labscribe3 software (iWorx) and the last 20 s of the 
traces were used to determine the PR and QT intervals, averaging every 30 beats. The QT 
interval was corrected for heart rate (QTc), calculated using the QT and RR intervals with the 
Bazett’s formula, adjusted for mice: QTc = QT/(RR/100)0.5. 
The QT interval (which coincides well with the action potential duration; APD13) increased 
between sham and MI mice in both groups as expected13, but there was no significant 
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difference in QT interval between control and Runx1D/D mice post-MI (Supplemental Material 
Figure 9A&B). 
 
Determination of the action potential duration in cardiomyocytes isolated from 
Runx1Δ/Δ and control hearts 2 wk-post-MI.  
Voltage recordings were made on isolated cardiomyocytes using the CellOPTIQTM  
electrophysiology platform (Clyde Bioscience Ltd., Glasgow, UK). Cells were loaded with 
8 µmol/L Di-4 ANEPPS, and illuminated using a 470nm OptoLED (Cairn Research; 
Faversham, UK). The APD was measured at a range of lengths (APD20, 40, 60 and 80) and 
demonstrated no significant difference between control and Runx1D/D mice post-MI. Together 
with the ECG measurements above, the experiments demonstrated that an increased APD 
cannot account for the changes in Ca2+ handling between control and Runx1D/D mice post-MI 
(Supplemental Material Figure 9C&D). 
 
Determination of calcium entry in cardiomyocytes isolated from Runx1Δ/Δ and control 
hearts 2 wk-post-MI.  
Fura-4F (8 µmol/L)-loaded cardiomyocytes were alternately excited between 360 and 
380nm with emission collected at 510nm and electrically paced using field stimulation 
(2ms, 40V, 1Hz). Two previously published protocols were used to measure the amplitude 
of the Ca2+ transient in the absence of SR Ca2+ release (an index of Ca2+ influx via the L-type 
Ca2+ channel). The first protocol measured the amplitude of the first stimulated Ca2+ 
transient immediately after application of 10mM caffeine (to empty Ca2+ from the 
sarcoplasmic reticulum; SR)14, 15 (Supplemental Material Figure 9E&F) and in separate 
experiments, the second protocol measured the amplitude of the stimulated Ca2+ transient 
during inhibition of the SR with thapsigargin (1µmol/L for 30 min; Supplemental Material 
Figure 9G)16. Both protocols confirmed that there was no change in the amplitude of Ca2+ 
influx between control and Runx1D/D mice post-MI. Collectively, these experiments 
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demonstrated that an increased Ca2+ entry cannot account for the changes in Ca2+ handling 
between control and Runx1D/D mice post-MI. 
 
Viral overexpression of Runx1 in culture 
Adult rabbit cardiomyocytes were isolated as described above but in sterile filtered isolation 
MIKH. The [Ca2+] in solution ([Ca2+]o) was raised in this suspension via stepwise increments 
until 1.0 mmol/L was reached. Cardiomyocytes were gently centrifuged in a hand-operated 
centrifuge and resuspended in prewarmed minimal essential media (MEM; Life 
Technologies) supplemented with L-glutamine and penicillin–streptomycin plus 10% fetal 
calf serum (FCS). The cells were added to wells of a 6-well tissue culture plate at a density 
of 1 x 105 rods per well and incubated at 37˚C in 5% CO2 for 1–2 h to allow the 
cardiomyocytes to adhere to the base of the well. The media was carefully aspirated under 
sterile conditions. Freshly warmed MEM without FCS was added to each well. Adenovirus 
was previously prepared with cloned genes for GFP (control Ad-GFP) or Runx1 with GFP 
(experimental Ad-Runx1) using standard protocols17, 18. Aliquots of each virus were thawed 
and diluted to 1:100 with warmed MEM. The PFU of each virus was 2.54 x 1010 for Ad-
Runx1 and 1.10 x 1011 for Ad-GFP. The volume of the virus required for infection was 
calculated based on the number of rod-shaped cardiomyocytes and the PFU of the virus. 
Cultures were maintained at 37˚C in 5% CO2 for 24 h.  
 
REFERENCES 
 
1. Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger 
JM and Molkentin JD. Temporally regulated and tissue-specific gene manipulations in the 
adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001;89:20-25. 
2. Hall ME, Smith G, Hall JE and Stec DE. Systolic dysfunction in cardiac-specific 
ligand-inducible MerCreMer transgenic mice. Am J Physiol Heart and Circ Physiol. 
2011;301:H253-60. 
13 
 
3. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E and Speck NA. Runx1 is required for 
the endothelial to haematopoietic cell transition but not thereafter. Nature. 2009;457:887-91. 
4. Gilsbach R, Preissl S, Gruning BA, Schnick T, Burger L, Benes V, Wurch A, Bonisch 
U, Gunther S, Backofen R, Fleischmann BK, Schubeler D and Hein L. Dynamic DNA 
methylation orchestrates cardiomyocyte development, maturation and disease. Nat 
Commun. 2014;5:5288. 
5. Bergmann O, Zdunek S, Alkass K, Druid H, Bernard S and Frisen J. Identification of 
cardiomyocyte nuclei and assessment of ploidy for the analysis of cell turnover. Exp Cell 
Res. 2011;317:188-94. 
6. Preissl S, Schwaderer M, Raulf A, Hesse M, Gruning BA, Kobele C, Backofen R, 
Fleischmann BK, Hein L and Gilsbach R. Deciphering the Epigenetic Code of Cardiac 
Myocyte Transcription. Circ Res. 2015;117:413-23. 
7. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ and 
Luo Y. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-
embedded tissues. J Mol Diagn. 2012;14:22-9. 
8. Clark JE and Marber MS. Advancements in pressure-volume catheter technology - 
stress remodelling after infarction. Exp Physiol. 2013;98:614-21. 
9. Takagawa J, Zhang Y, Wong ML, Sievers RE, Kapasi NK, Wang Y, Yeghiazarians Y, 
Lee RJ, Grossman W and Springer ML. Myocardial infarct size measurement in the mouse 
chronic infarction model: comparison of area- and length-based approaches. J Appl Physiol 
(1985). 2007;102:2104-11. 
10. Bohl S, Medway DJ, Schulz-Menger J, Schneider JE, Neubauer S and Lygate CA. 
Refined approach for quantification of in vivo ischemia-reperfusion injury in the mouse heart. 
Am J Physiol Heart Circ Physiol. 2009;297:H2054-H2058. 
11. Elliott EB, Hasumi H, Otani N, Matsuda T, Matsuda R, Kaneko N, Smith GL and 
Loughrey CM. K201 (JTV-519) alters the spatiotemporal properties of diastolic Ca2+ release 
and the associated diastolic contraction during beta-adrenergic stimulation in rat ventricular 
cardiomyocytes. Basic Res Cardiol. 2011;106:1009-22. 
14 
 
12. Zhang M, Prosser BL, Bamboye MA, Gondim AN, Santos CX, Martin D, Ghigo A, 
Perino A, Brewer AC, Ward CW, Hirsch E, Lederer WJ and Shah AM. Contractile Function 
During Angiotensin-II Activation: Increased Nox2 Activity Modulates Cardiac Calcium 
Handling via Phospholamban Phosphorylation. J Am Coll Cardiol. 2015;66:261-72. 
13. Boukens BJ, Rivaud MR, Rentschler S and Coronel R. Misinterpretation of the 
mouse ECG: 'musing the waves of Mus musculus'. J Physiol. 2014;592:4613-26. 
14. Elliott EB, McCarroll D, Hasumi H, Welsh CE, Panissidi AA, Jones NG, Rossor CL, 
Tait A, Smith GL, Mottram JC, Morrison LJ and Loughrey CM. Trypanosoma brucei 
cathepsin-L increases arrhythmogenic sarcoplasmic reticulum-mediated calcium release in 
rat cardiomyocytes. Cardiovasc Res. 2013;100:325-35. 
15. Trafford AW, Diaz ME, Negretti N and Eisner DA. Enhanced Ca2+ current and 
decreased Ca2+ efflux restore sarcoplasmic reticulum Ca2+ content after depletion. Circ Res. 
1997;81:477-484. 
16. Elliott EB, Kelly A, Smith GL and Loughrey CM. Isolated rabbit working heart function 
during progressive inhibition of myocardial SERCA activity. Circ Res. 2012;110:1618-27. 
17. Theriault FM, Nuthall HN, Dong Z, Lo R, Barnabe-Heider F, Miller FD and Stifani S. 
Role for Runx1 in the Proliferation and Neuronal Differentiation of Selected Progenitor Cells 
in the Mammalian Nervous System. J Neurosci. 2005;25:2050-2061. 
18. Nicklin SA and Baker AH. Simple methods for preparing recombinant adenoviruses 
for high-efficiency transduction of vascular cells. Methods Mol Med. 1999;30:271-83. 
 
Supplemental Material Figure 1. Control RNAscope probes. Typical control heart section 
images of (A) negative dapB and (B) positive PPIB and POLR2 probes taken from the right 
ventricle (RV), left ventricle (LV), border zone (BZ) and infarct (INF) regions in MI hearts 1 
day post-MI or the equivalent regions in sham hearts.  
 
Supplemental Material Figure 2. Runx1 expression in WT C57BL/6 mice post-MI. (A) 
Typical PV loop traces at 4 weeks post-MI and mean data (n=10 sham, n=13 MI; *P<0.05, 
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Student’s t-test) for; (B) Left ventricular (LV) End-systolic pressure, (C) maximum rate of 
contraction, (D) LV end-diastolic pressure, (E) maximum rate of relaxation, (F) LV end-
systolic volume, (G) LV end-diastolic volume and (H) Ejection fraction. (I) Whole heart 
Runx1 mRNA (n=6 sham, n=7 MI; *P<0.05, Student’s t-test). (J) MI heart (BZ,border zone; 
LV,left ventricle; INF,infarct; RV,right ventricle; Scale=1mm). (K) Regional Runx1 mRNA 4 
wk post-MI (n=4 sham, n=8 MI). #P<0.05 relative to RV and *P<0.05 sham versus MI, 
Student’s t-test. (RQ,relative quantification). (L) Regional Runx1 protein 3 wk post-MI (n=5), 
with (M) mean data (ANOVA).  
 
Supplemental Material Figure 3. Regional Runx1 mRNA 8 wk post-MI 
Runx1 mRNA in different regions (INF, infarct; BZ, border zone and LV, left ventricle) of 8 wk 
post-MI hearts (n=4 sham, n=6 MI; *P<0.05 Student’s t-test). 
 
Supplemental Material Figure 4. Echocardiography study – cardiac contractile 
function in C57Bl/6J mice. 1 wk post-MI echocardiography study measuring fractional 
shortening in WT C57Bl/6J sham (n=3-5) and MI (n=3-6) mice; *P<0.05 Student’s t-test. 
 
Supplemental Material Figure 5. Generation of Runx1Δ/Δ mice. (A) The RUNT domain 
and locations of the three primers (colored arrows) used to detect the Runx1wt/wt, Runx1fl/fl 
and excised Runx1Δ/Δ alleles. LoxP sites are indicated by blue triangles. (B) PCR of genomic 
DNA; whole hearts from male (M) and female (F) mice (Runx1Δ/Δ n=9 for M and n=4 for F; 
Runx1fl/fl n=8 for M and n=6 for F; Runx1wt/wt n=6 for M and n=6 for F). A WT and three-band 
control where used to delineate the appropriate sized bands (bands 1 and 2). (C) PCR of 
genomic DNA; WT and three-band controls (bands 1 and 2), whole heart preparations 
(bands 3–5), cardiomyocytes (CMs) from Runx1Δ/Δ mice that had been separated from other 
cell types by plating and short term culture (band 6) or by FACS (band 7). Mean ± SEM of 
Runx1 excision as denoted by the ratio of the excised band (310 bp) to the combined 
excised (310 bp) and LoxP band (275 bp) (band 5 [n=3], band [n=4)] and band 7 [n=2]), 
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*P<0.05 ANOVA. (D) Runx1 mRNA levels (relative to PPIB; 2-ΔCt) in whole heart tissue from 
the right ventricle (RV), left ventricle (LV), border zone (BZ) and infarct (INF) regions of 4 wk 
post-MI hearts (Runx1Δ/Δ MI [n=5 hearts] as % of Runx1wt/wt and Runx1fl/fl MI [n=9 hearts] 
*P<0.05 Student’s t-test). (E) Runx1 mRNA levels (relative to PPIB; 2-ΔCt) in cardiomyocytes 
separated from other cell types by plating and short term culture from 2 wk post-MI hearts 
(Runx1Δ/Δ MI [n=7 hearts] as % of Runx1fl/fl MI [n=8 hearts], *P<0.05 Student’s t-test). (F; 
Left) Western blot of Runx1 in isolated cardiomyocytes from 2 wk post-MI hearts with pan-
actin loading control (performed on same blot as Figure 6A) and thymus (Thy) positive 
control for Runx1. (F; Right) Percentage change in Runx1 protein in isolated 
cardiomyocytes from 2 wk post-MI hearts (Runx1Δ/Δ MI [n=5 hearts] as % of  Runx1wt/wt and 
Runx1fl/fl MI [n=5 hearts], *P<0.05 Student’s t-test).  
 
Supplemental Material Figure 6. Blinded study – cardiac function assessed by 
echocardiography in Runx1Δ/Δ mice. 2 wk post-MI blinded study (control Runx1fl/fl MI 
(n=8), Runx1wt/wt MI (n=11) and Runx1Δ/Δ MI (n=7), *P<0.05 ANOVA) for the following 
functional parameters: (A) Fractional shortening (FS), (B) Left ventricular internal diameter 
at systole (LVIDs), (C) LVID at diastole (LVIDd), (D) LV posterior wall thickness at systole 
(LVPWs), (E) LVPW thickness at diastole (LVPWd). 
 
Supplemental Material Figure 7. Echocardiography study – cardiac contractile 
function in Runx1Δ/Δ mice. 1 wk post-MI echocardiography study measuring fractional 
shortening in Runx1Δ/Δ MI (n=5-6) and control Runx1fl/fl MI and Runx1wt/wt MI mice combined 
(n=5-10); *P<0.05 Student’s t-test. 
 
Supplemental Material Figure 8. Infarct size at 24 h post-myocardial infarction (MI) and 
post-ischemia reperfusion (I/R). (A) Typical heart section images of MI using TTC 
staining. (B) Mean infarct area (IA) as % of left ventricle (LV) [control MI (n=8) and Runx1Δ/Δ 
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MI (n=5), *P<0.05 Student’s t-test]. (C) Typical heart section images of IR using TTC 
staining. (D) Mean area at risk (AAR) as % LV (left) and IA as % of AAR (right) [control MI 
(n=6) and Runx1Δ/Δ MI (n=4), *P<0.05 Student’s t-test]. Scale bar: 1mm Linear adjustment of 
contrast, brightness or color were applied equally to all parts of the image. 
 
Supplemental Material Figure 9. Isolated cardiomyocyte electrical activity in Runx1Δ/Δ 
mice. (A) Typical electrocardiogram (ECG) traces from control and Runx1Δ/Δ and mice 2 wk-
post-MI with (B) mean QT and QTc (corrected) intervals of control Runx1fl/fl and Runx1wt/wt 
mice combined (n=4 sham; n=10 MI) and Runx1Δ/Δ (n=4 sham; n=6 MI), *P<0.05 Student’s t-
test. (C) Typical voltage recordings on isolated cardiomyocytes from control and Runx1Δ/Δ 
and mice 2 wk-post-MI with (D) mean action potential duration (APD) at a range of lengths 
(APD20, 40, 60 and 80) of control Runx1fl/fl MI and Runx1wt/wt MI mice combined (n=28 
cardiomyocytes, 6 hearts) and Runx1Δ/Δ MI (n=18 cardiomyocytes, 5 hearts). (E) Typical 
calcium measurements of the Ca2+ transient in the absence of SR Ca2+ release in isolated 
cardiomyocytes from control and Runx1Δ/Δ and mice 2 wk-post-MI with (F) mean amplitude 
of the first stimulated Ca2+ transient immediately after application of 10mM caffeine of control 
Runx1fl/fl MI and Runx1wt/wt MI mice combined (n=31 cardiomyocytes, 7 hearts) and Runx1Δ/Δ 
MI (n=11 cardiomyocytes, 3 hearts). (G) Mean amplitude of the stimulated Ca2+ transient 
during thapsigargin-mediated SR inhibition of control Runx1fl/fl MI and Runx1wt/wt MI mice 
combined (n=6 cells; 2 hearts) and Runx1Δ/Δ MI (n=5 cells; 2 hearts). 
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